Envista Holdings earnings date
Want to see NVST full AI Analyst Report?
Envista Holdings (NVST) Q3 2026 Earnings Report
NVST Q3 2026 EPS Results
- Actual EPS
- $0.40
- Consensus EPS
- $0.36
- Beat/Miss
- Beat by +$0.04
- One Year Ago EPS
- $0.32
NVST Q3 2026 Revenue Results
- Actual Revenue
- $691.50M
- Expected Revenue
- $688.74M
- Beat/Miss
- Beat by +$2.77M
- YoY Revenue Growth
- +3.22%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Envista Holdings's next earnings date is estimated for February 10, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was broadly positive, supported by solid third-quarter sales and earnings growth, margin expansion, strong cash flow, a raised full-year outlook, share gains in diagnostics and Spark, and continued operational and innovation progress. The main challenges were a soft U.S. market, weaker elective categories, China destocking and upcoming VBP pricing pressure, plus an implied slight fourth-quarter core sales decline and foreign exchange headwinds. Overall, the positive operating and financial trends significantly outweighed the stated challenges.
Envista raised and narrowed its full year 2026 guidance to core sales growth of 3.75% to 4.25%, adjusted EBITDA growth of 12.5% to 14% and adjusted EPS of $1.54 to $1.58, compared with prior ranges of 3.5% to 4.5% and $1.50 to $1.55, with adjusted EPS up more than 10% at the midpoint from the initial 2026 guide; it continues to expect free cash flow conversion of approximately 100% for the full year and a full year tax rate of around 25.5% of adjusted pretax income, while fourth quarter guidance implies slightly negative core sales growth, or growth consistent with the full year range excluding 4 fewer selling days, with foreign exchange expected to reduce reported fourth quarter revenue growth by approximately 1 percentage point, acquisitions contributing approximately 0.5 percentage point, no significant VBP-related impact in the fourth quarter, and VBP implementation most likely to commence in the first half of 2027.
- Strong Third-Quarter Earnings GrowthThird-quarter sales were $691 million, up $21 million year over year, with core sales growth of 2.7% and total growth of 3.2%. Adjusted EBITDA increased 9% to approximately $106 million, adjusted EPS rose 25% to $0.40, and adjusted EBITDA margin expanded 80 basis points to 15.3%.
- Margin Expansion Despite Continued InvestmentAdjusted gross margin reached 56.3%, up 20 basis points year over year, driven primarily by price and factory productivity. Price, procurement and factory productivity efforts offset inflationary pressures and supported gross and EBITDA margin expansion while the company continued investing in new products and commercial capabilities.
- Broad-Based Portfolio and Geographic GrowthBoth reporting segments and all major geographies aside from China were in positive territory. Developed markets grew mid-single digits, emerging markets grew low single digits overall and high single digits excluding China, Europe grew mid-single digits, developing markets excluding China grew high single digits, and North America grew low single digits.
- Growth in Key Product CategoriesSpark sales grew at a high-single-digit rate, diagnostics and implants each grew mid-single digits, and consumables grew low single digits despite a high 2025 comparison and strong first-half performance.
- Equipment and Consumables Segment PerformanceEquipment & Consumables delivered more than 4% core growth, with diagnostics up mid-single digits and consumables up low single digits. Diagnostics grew across hardware, software and services, and the segment's adjusted operating profit increased more than 15% year over year, supported by volume, price and operating efficiency.
- Diagnostics Share Gains and Integrated OfferingThe company reported gaining share in diagnostics, particularly in North America, where it is the number-one player with the largest installed base globally. Management attributed the position to its installed base, updated CBCT, IOS and handheld 2D platforms, and an integrated hardware, software and service offering.
- Specialty Products and Technologies Growth DriversSpecialty Products & Technologies revenue was $444 million, up nearly 3% year over year with 2% core growth. Spark grew high single digits, implants grew mid-single digits across all geographies, and implant growth benefited from new product introductions, regenerative biomaterials and the Versah acquisition.
- Successful Versah IntegrationManagement said the integration of the Versah acquisition continues to go well, with growth and profitability both ahead of plan.
- Raised Full-Year 2026 GuidanceThe company raised and narrowed its full-year outlook to core sales growth of 3.75% to 4.25%, compared with the prior range of 3.5% to 4.5%; adjusted EBITDA growth of 12.5% to 14%; and adjusted EPS of $1.54 to $1.58, compared with the prior range of $1.50 to $1.55. The midpoint of the updated EPS range is up more than 10% from the initial 2026 guide, and the company continues to expect approximately 100% free cash flow conversion for the full year.
- Strong Cash Flow and Balance SheetFree cash flow was $63 million in the quarter, representing 97% conversion of adjusted net income. Net debt to adjusted EBITDA was approximately 0.6x, providing capital deployment flexibility. The company repurchased around 400,000 shares for roughly $10 million and received refunds for essentially all IEEPA tariffs paid in 2025.
- Tax Rate ImprovementThe effective tax rate declined by almost 6 percentage points versus the third quarter of 2025. Management expects the full-year tax rate to be around 25.5% of adjusted pretax income, consistent with the third quarter and year-to-date average.
- Innovation Pipeline and New Product LaunchesThe company introduced NOMAD Pro 3, a handheld X-ray system with improved image quality and 10x less rear-directed radiation than the leading competitor; the lighter Ultra HDL prismatic loupe from Orascoptic; and an AI-assisted Endo Module for DTX Studio that supports canal segmentation, clinical decision-making, treatment planning and patient communications. Management said the new product pipeline has never been richer and that returns from increased new product investment are becoming increasingly clear.
- Continued Investment in Growth CapabilitiesEnvista has meaningfully increased new product investment in each of the last two years and continues to invest in R&D, sales and marketing, commercialization and talent development. Management said year-over-year R&D investment has increased at double-digit rates in recent years, while new product launches across implants, diagnostics, orthodontics and consumables are still below their full long-term potential.
- Operational Productivity and Organizational ProgressThe company conducted more than 40 Kaizen events in the quarter across three continents, opened a new European Spark design center in Madrid, and reported that G&A expense as a percentage of sales is down almost 3 percentage points over two years. Gross margin has expanded for three consecutive quarters.
- Sustainability and Community ImpactEnvista's 2025 sustainability report highlighted a 17% year-over-year reduction in lost-time injuries, a 19% reduction in water consumption and a 40% reduction in waste generation. The Envista Smile Project served close to 20,000 patients in the prior year, with additional care delivered in the quarter across the United States, Ghana, Mexico, Honduras and Costa Rica.
- Improving Long-Term Performance Metrics and Employee EngagementManagement said year-to-date 2026 core growth is up more than 6 points from the same period in 2024 and year-to-date EBITDA dollars have grown more than 50%. Employee scores have increased for three consecutive years, and the company has added talent development programs to deepen its leadership bench.
- Clear Aligner Expansion Opportunity in JapanManagement described Japan as a roughly $200 million clear aligner market, where Spark launched in January with no prior share and is growing very quickly. The company expects to compete for as much of that market as it can obtain.
- Capital Allocation FrameworkManagement reiterated that organic investment is the first capital allocation priority, M&A is the second, and shareholder returns have been added as a capital allocation priority. The company expects share repurchases to represent roughly one-third of annual free cash flow while continuing to evaluate bolt-on acquisitions and geographic expansion opportunities.
NVST Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 10, 2027 | 2026 (Q4) | 0.40- | 0.38 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | 0.360.40 | 0.32 | 25.00% (+0.08) | |
| Aug 05, 2026 | 2026 (Q2) | 0.340.41 | 0.26 | 57.69% (+0.15) | |
| May 06, 2026 | 2026 (Q1) | 0.310.36 | 0.24 | 50.00% (+0.12) | |
| Feb 05, 2026 | 2025 (Q4) | 0.320.38 | 0.24 | 58.33% (+0.14) | |
| Oct 29, 2025 | 2025 (Q3) | 0.280.32 | 0.12 | 166.67% (+0.20) | |
| Jul 31, 2025 | 2025 (Q2) | 0.230.26 | 0.11 | 136.36% (+0.15) | |
| May 01, 2025 | 2025 (Q1) | 0.200.24 | 0.26 | -7.69% (-0.02) | |
| Feb 05, 2025 | 2024 (Q4) | 0.220.24 | 0.29 | -17.24% (-0.05) | |
| Oct 30, 2024 | 2024 (Q3) | 0.090.12 | 0.43 | -72.09% (-0.31) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


